Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

methylphenidate HCl

- PMLiVE

Pfizer’s one-time haemophilia B gene therapy Durveqtix granted EC approval

More than 42,000 people globally are living with the rare bleeding disorder

- PMLiVE

Pfizer shares positive late-stage results for haemophilia A gene therapy

The rare bleeding disorder occurs in approximately 25 in every 100,000 male births globally

- PMLiVE

UK government announces national RSV vaccination programme for infants and older adults

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

- PMLiVE

Pfizer to advance once-daily formulation of oral GLP-1 receptor agonist danuglipron

The drugmaker said last year that it would be dropping its twice-daily formulation of the candidate

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

The vaccine generated an improved response against several Omicron JN.1 sublineages

- PMLiVE

Pfizer shares positive overall survival results for Elrexfio in multiple myeloma

The blood cancer is responsible for more than 187,000 new cases worldwide every year

- PMLiVE

Pfizer/Flagship’s drug discovery partnership to focus on obesity treatments

The agreement with Profound Therapeutics is the first to be initiated under the partnership

- PMLiVE

Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

- PMLiVE

Pfizer shares positive five-year results for Lorbrena in advanced lung cancer

The majority of Lorbrena-treated patients were alive without disease progression after five years

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Pfizer’s Vyndaqel recommended by NICE to treat rare heart disease ATTR-CM

Approximately 1,500 people in England are affected by transthyretin amyloidosis cardiomyopathy

- PMLiVE

Pfizer’s sickle cell disease therapy Oxbryta recommended by NICE for NHS use

About 4,000 people in England with the genetic blood disorder are expected to benefit from the decision

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links